DEVELOPMENT OF NANOEMULSION TO IMPROVE THE OCULAR BIOAVAILABILITY AND PATIENT COMPLIANCE IN POSTOPERATIVE TREATMENT USING INDOMETHACIN
Objective: To develop a new cationic nanoemulsion (NE) for ophthalmic delivery of indomethacin (IND) to improve the permeability and retention time of formulations, thereby improving the drug's ocular bioavailability.
Methods: Based on the solubility profile of indomethacin in various solvents, captex 8000 was selected as oil phase, span 20 as a surfactant and tween 20 as co-surfactant to construct pseudo ternary phase diagrams and nanoemulsion region was recognized. Sonication was used as the method of NE preparation. Optimization was done using 32 factorial designs by considering the oil and the ratio of surfactant to co-surfactant (Smix) quantities as independent variables and evaluated for different physicochemical properties. Ex vivo transcorneal permeability was studied using bovine cornea, the In vivo drug pharmacokinetics of optimized NE and marketed formulation were assessed in rabbit aqueous humor and also in plasma.
Results: The mean globule size, zeta potential, viscosity, refractive index, pH, surface tension and the osmolarity values for the prepared indomethacin nanoemulsions (IND-NEs) were found between 129.8±1.1 to 191.4±1.6 nm,+13.20±4.6 to+23.45±4.82, 15.3±0.1 to 32.7±0.0 mPas, 1.346±0.007 to 1.386±0.005, 5.5±0.4 to 6.9±0.9, 32.0±2.6 to 52.3±3.4 mN/m and 303-395 mOsm/l respectively and all these values found to be falling under the recommended values for ophthalmic use. From the In vitro release studies, it was found that the IND-NEs exhibited sustained drug release with 67.91±2.01 to 95.90±1.93 % drug release at 24h when compared to the drug solution which showed 99.81±5.21 % drug release within 2h. The Ex vivo drug permeation through the corneal membrane at 4h from the optimized NE and drug solution was found to be 524±1.5 µg/cm2 and 175±2.6 µg/cm2 respectively. Further, the optimized NE was found to be nonirritant with the lowest ocular irritation potential (Iirr) of 1 towards the rabbit's eyes. The area under the drug concentration vs. time curve for 24h (AUC (0–24h)) for optimized NE and the marketed formulation was found to be 1514.99 ng/ml/h and 974.14 ng/ml/h in aqueous humour; 2266.83 ng/ml/h and 778.15 ng/ml/h in plasma respectively.
Conclusion: Due to its improved corneal absorption and prolonged drug release along with less systemic absorption, the optimized NE offers an effective postoperative treatment with increased ocular bioavailability and improved patient compliance with a decrease in the number of installations per day and a decrease or disappearance of systemic side effects of IND.
2. Ahuja M, Dhake AS, Sharma SK, Majumdar DK. Topical ocular delivery of NSAIDs. AAPS J 2008;10:229–41.
3. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: an overview. World J Pharmacol 2013;2:47–64.
4. Shulin D. Recent developments in ophthalmic drug delivery. Pharm Sci Technol Today 1998;1:325-38.
5. Pranita S, Amrita B. Nanoemulsions-a review. Int J Res Pharm Chem 2016;6:312-22.
6. Ankur GA, Burak EH, Alan HT, Patrick DS. Nanoemulsions: formation, properties and applications. Soft Matter 2016;12:1-16.
7. Hegde RR, Verma A, Ghosh A. Microemulsion: New Insights into the ocular drug delivery. ISRN Pharm 2013;2013:1-11.
8. Li G, Jing W, Min J, Hanah B, Ouyang D, Frank E, et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers. Drug Discovery Today 2013;18:290-7.
9. Boyka T, Ivanka P, Alexander Z, Plamen P. Performance liquid chromatographic assay of indomethacin and its related substances in tablet dosage forms. Int J Pharm Pharm Sci 2012;4:549-52.
10. Adnan A, Rizwan M, Farhan JA, Zeenat I, Roop KK, Aqil M, et al. Nanoemulsion components screening and selection: a technical note. AAPS PharmSciTech 2009;10:69-76.
11. Cristhian Yarce. The HLB system: a timesaving guide to emulsifier selection. Wilmington [DE]: ICI Americas Inc; 1992.
12. Parasuram RR, Guruprasad S. Nanoemulsion based emulgel formulation of lipophilic drug for topical delivery. Int J Pharmtech Res 2016;9:210-23.
13. Georgeta C, Vicen?iu V, Ioana O, Ana MM, Dan FA, Cornelia I, et al. Development and evaluation of new micro emulsion-based hydrogel formulations for topical delivery of fluconazole. AAPS PharmSciTech 2015;16:889-904.
14. Muza MR, Taha UW, Neeraj M, Hasham SS, Roqia A, Faheem SA. Development and characterization of drug-loaded self-solidnano-emulsified drug delivery system for treatment of diabetes. Mater Sci Res India 2018;15:1-11.
15. Patel N, Nakrani H, Raval M, Sheth N. Development of loteprednol etabonate-loaded cationic nano emulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Drug Delivery 2016;23:3712–23.
16. Sneha P, Marina K, Suchetha Kumari N. Nanoemulsion components screening of quetiapine fumarate: effect of surfactant and co-surfactant. Asian J Pharm Clin Res 2015;8:136-40.
17. Shah J, Nair AB, Jacob S, Patel RK, Shah H, Shehata TM, et al. Nanoemulsion based vehicle for effective ocular delivery of moxifloxacin using experimental design and pharmacokinetic study in rabbits. Pharmaceutics 2019;11:230-46.
18. Chikte AA, Umekar MJ, Borkhade MN, Raut NS. Effect of transesterification of oil on nanoemulsion gel for topical drug delivery. Int J Pharm Sci Res 2018;9:589-98.
19. Ali MS, Alam MS, Alam N, Siddiqui MR. Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. Iran J Pharm Res 2014;13:1125–40.
20. Syafinaz Z, Mahiran B, Emilia AM. Formulation optimization of a palm-based nanoemulsion system containing levodopa. Int J Mol Sci 2012;13:13049-64.
21. Pratap SB, Brajesh K, Jain SK, Shafaat K. Development and characterization of a nanoemulsion gel formulation for transdermal delivery of carvedilol. Int J Drug Dev Res 2012;4:151-61.
22. Florence AT, Attwood D. Physicochemical properties of drugs in solution: physicochemical principles of pharmacy. 4th ed. Pharmaceutical Press; 2006. p. 69-73.
23. Harwansh RK, Patra KC, Pareta SK, Singh J, Rahman MA. Nanoemulsions as vehicles for transdermal delivery of glycyrrhizin. Braz J Pharm Sci 2011;47:769-78.
24. Mowafaq GM, Abulfadhel NJ. Formulation and characterization of nimodipine nanoemulsion as ampoule for oral route. Int J Pharm Sci Res 2017;8:591-602.
25. Khalid N, Gaofeng S, Brenden HJ, Kobayashid I, Mitsutoshi N, Colin Barrowa J. Formulation and characterization of O/W nanoemulsions encapsulating high concentration of astaxanthin. Food Res Int 2017;102:364–71.
26. Usha GK, Sree HN, Balakeshwa R, Prakash RB, Subramanian R. Enhanced trans-corneal permeability of valacyclovir by polymethacrylic acid copolymers based ocular microspheres: in vivo evaluation of estimated pharmacokinetic/pharmacodynamic indices and simulation of aqueous humor drug concentration-time profile. J Pharm Innov 2016;11:82–91.
27. Laxman M. Electron microscopy as a tool in research and disease diagnosis. Lead paper compendium published and presented in IAVP annual conference XXXI, held at Anand, Gujarat, India; 2014. p. 139-60.
28. Agarwal P, Rupenthal ID. In vitro and ex vivo corneal penetration and absorption models. Drug Delivery Transl Res 2016;6:634–47.
29. Maria SM, Maria ACP, Vicent R, Cristina BF, Alicia LC. Ex vivo rabbit cornea diffusion studies with a soluble insert of moxifloxacin. Drug Delivery Transl Res 2018;8:132–9.
30. Peter WJM, Natalia NP, Sukhmanpreet C, Lgiz AS, Charlene L, Irina IS, et al. Crown ethers: novel permeability enhancers for ocular drug delivery. Mol Pharm 2017;14;3528?38.
31. Lou J, Hu W, Tian R, Zhang H, Jia Y, Zhang J, et al. Optimization and evaluation of a thermoresponsive ophthalmic in situ gel containing curcumin-loaded albumin nanoparticles. Int J Nanomed 2014;9:2517-25.
32. Marongiu ML, Gulinati A, Floris B. A procedure for rabbit blood serial collection. Ital J Anim Sci 2007;6:773-9.
33. Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother 2010;1:87-93.
34. Rajendra SK, Gajanan J, Miller O, Uday BK. Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow. Drug Metab Dispos 2011;39:1529-37.
35. Sonia HT, Ehab EF, Rawda SM. Simultaneous determination of timolol maleate in combination with some other anti-glaucoma drugs in rabbit aqueous humor by high-performance liquid chromatography-tandem mass spectroscopy. J Chromatogr B 2016;1022:109–17.
36. Shital PS, Rajesh PK, Abhishek JB, Ahmed AA, Jamaan A, Shital BB. Anti-inflammatory and antioxidative stress effects of oryzanol in glaucomatous rabbits. J Ophthalmol 2017;2017:1-9.
37. Lucia P, Diego RP, Giulia B, Marco C, Giovanni FP. An overview of micro-and nanoemulsions as vehicles for essential oils: formulation, preparation and stability. Nanomaterials 2020;10:2-24.
38. Lallemand F, Daull P, Simon B, Ronald B, Garrigue JS. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Delivery 2012;1-16. Doi:10.1155/2012/604204
39. Baranowski P, Karolewicz B, Gajda M, Pluta J. Ophthalmic drug dosage forms: characterization and research methods. Sci World J 2014;2014:1-14.
40. Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech 2009;10:808-19.
41. Morsi NM, Mohamed MI, Refai HM, Sorogy EL. Nanoemulsion as a novel ophthalmic delivery system for acetazolamide. Int J Pharm Pharm Sci 2014;6:227-36.
42. Zainol S, Basri M, Basri HB. Formulation optimization of a palm-based nanoemulsion system containing levodopa. Int J Mol Sci 2012;13:13049–64.
43. Koteswari P, Rama KS, Prabhakar RV, Lakshmi NM. Formulation and preparation of felodipine nanoemulsions. Asian J Pharm Clin Res 2011;4:116-7.
44. Yadav P, Vaibhav R, Verma A. Application of Box–Behnken design and desirability function in the development and optimization of self-nano emulsifying drug delivery system for enhanced dissolution of ezetimibe. Future J Pharm Sci 2020;6:2-20.
45. Sayed S, Ibrahim E. Tailored nanostructured platforms for boosting transcorneal permeation: box–behnken statistical optimization, comprehensive in vitro, ex vivo and in vivo characterization. Int J Nanomed 2017;12:7947–62.
46. Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol 2014;66:531–41.
47. Ban J, Zhang Y, Huang X, Deng GH, Hou DZ, Chen YZ, et al. Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone. Int J Nanomed 2017;12:1329–39.
This work is licensed under a Creative Commons Attribution 4.0 International License.